Acute non-haemolytic anemia after short administration of L Dopa plus Benserazide
Pezzoli, G.; Passerini, D.; Scarlato, G.; Radaelli, F.
Annals of Allergy 48(6): 362
1982
ISSN/ISBN: 0003-4738 PMID: 7091780 Document Number: 193355
Document emailed within 1 workday
Related Documents
Casacchia, M.; Barba, C.; Ruggieri, S.; Zamponi, A.; Agnoli, A. 1974: Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination Rivista di Neurologia 44(5): 303-330Boismare, F.; Samson, M.; Pouliquen, A.; Hacpille, L. 1976: Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa Therapie 31(5): 615-622
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Bhuyan, U.N.; Srivastava, R.N.; Choudhry, V.P. 1985: Pathology of acute renal failure and haemolytic uraemic syndrome in acute dysentery in children Indian Journal of Medical Research 81: 402-408
Lijnen, P.; M'Buyamba-Kabangu, J.R.; Lommelen, L.; Laermans, M.; Piccart, Y.; Fagard, R.; Staessen, J.; Amery, A. 1985: Intra-erythrocyte concentration and transmembrane fluxes of sodium and potassium during acute and short-term administration of ketanserin in normal male subjects Methods and Findings in Experimental and Clinical Pharmacology 7(9): 463-467
Hefti, F.; Melamed, E.; Wurtman, R.J. 1981: The site of dopamine formation in rat striatum after L-dopa administration Journal of Pharmacology and Experimental Therapeutics 217(1): 189-197
Clough, C.G.; Bergmann, K.J.; Yahr, M.D. 1984: Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration Advances in Neurology 40: 131-140
Dovedova, E.L. 1989: Mechanism of the action of the delta sleep-inducing peptide against a background of L-DOPA administration Biulleten' Eksperimental'noi Biologii i Meditsiny 107(4): 440-442
Grigor'eva, M.A.; Samoĭlova, R.S.; Ermakova, G.L.; Miterev, G.I.; Abakumov, E.M. 1983: The use of levamisole in infections and autoimmune hemolytic anemia in patients with chronic lymphoid leukemia and acute lymphoblastic anemia Gematologiia i Transfuziologiia 28(6): 29-32
Borne AE von dem; Engelfriet, C.P.; Beckers, D.; van Loghem, J.J. 1971: Autoimmune haemolytic anaemias. IV. Biochemical studies of red cells from patients with autoimmune haemolytic anaemia with incomplete warm autoantibodies Clinical and Experimental Immunology 8(3): 377-388
Burov, I.V.; Borisenko, S.A.; Kiianmaa, K.; Lehtosalo, J.; Mannisto, P. 1986: Effect of a single ethanol administration on the permeability of the hemato-encephalic barrier for 14C-tyrosine, 14C-DOPA and horseradish peroxidase Biulleten' Eksperimental'noi Biologii i Meditsiny 101(3): 331-334
Rizwan, M.; Maduemem, K.E. 2017: Idiopathic Atypical Haemolytic Uraemic Syndrome presenting with acute dystonia Irish Medical Journal 110(7): 622
Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871